HNSBF News and Press, Hansa Biopharma AB From 03/01/21

Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development Dr Korsgren to lead the research and development of Hansa's proprietary enzyme technology platform as the Com...

Hansa Biopharma to host conference call to provide Year-End report 2020 and Business Update PR Newswire LUND, Sweden , Jan. 27, 2021 /PRNewswire/ -- Hansa Biopharma will publish its Year-End report 2020 at 8:00 CET on February 4, 2021 . All interested par...

Hansa Biopharma to present at the 39th Annual J.P. Morgan Healthcare Conference The J.P. Morgan Healthcare Conference, the largest investment conference in the life science industry, will take place January 11-14, 2021 PR Newswire LUND, Sweden , Dec. 23, 2020 ...

Hansa Biopharma Nomination Committee formed PR Newswire LUND, Sweden, Nov. 2, 2020 LUND, Sweden , Nov. 2, 2020 /PRNewswire/ -- Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annua...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. With a nearly 60% weighting in the benchmark, U.S. stock ...

LUND, Sweden , Sept. 17, 2020 /PRNewswire/ -- Hansa Biopharma ("Hansa"), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company will host its 2020 Capital Markets Day (CMD) in Copenhagen on Thursday October 29 , from 13:3...

LUND, Sweden , July 16, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January - June, 2020. Highlights for the second quarter 2020    &#x...

Sarepta Therapeutics (NASDAQ: SRPT ) signs an agreement with Hansa Biopharma ( OTC:HNSBF ) for imlifidase , for rare Immunoglobulin G (IgG) mediated diseases. More news on: Sarepta Therapeutics, Inc., Hansa Biopharma AB (publ), Healthcare stocks news, Read more ...

LUND, Sweden , May 25, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the ongoing EMA review of imlifidase for a potential marketing authorization in Europe is on track. A CHMP opinion is expect...

LUND, Sweden , May 13, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team will participate in the following upcoming investor conferences: UBS Global Healthcare Confe...